Rajiv is Vice President and Head of Business Development at Jubilant Therapeutics. Previously he worked at Jubilant Biosys in which he held multiple senior positions heading departments such as Structural biology and Corporate Strategy & Business Development. During his tenure he on-boarded multiple integrated discovery programs, out-licensed assets to US based biotech’s and achieved several new benchmarks as an end-to-end innovative drug discovery solutions provider.

Prior to joining Jubilant he worked in Tumor immunology laboratory of Queensland Institute of Medical Research (QIMR) in Australia and in Brookhaven National laboratory on a structural genomics project headed by SGX Pharmaceutical. He has many publications in international journals apart from patent, abstracts and posters.

He has completed PhD in Biochemistry from University of Queensland, Australia had also completed MBA-professional from MSU, India.

Sridharan Rajagopal (Raj) is Vice President and Head of Medicinal Chemistry of Jubilant Therapeutics Inc. (JTx), a subsidiary of Jubilant Life Sciences Ltd. Raj brings a wealth of experience in drug discovery, medicinal chemistry and epigenetics to JTx. Prior to joining, he spent 5 years in various positions at Jubilant Biosys as Associate Director, Director and Associate Vice President, where under his leadership the company delivered several LO and preclinical candidates working with various small biotech and Big Pharma.

He also spent 7 years in various positions as Senior Scientist, Chief Research Scientist and Associate Director at Orchid Pharmaceuticals Ltd, India, where he was instrumental in developing a healthy pipeline in Oncology and Inflammation and advanced two candidates into the clinic in cancer and inflammation. He also worked for 2 years at Aurigene Discovery Technologies Ltd, India as Senior Scientist.

Raj has published nearly 25 peer-reviewed journal articles and holds 19 patents in drug discovery and development. He holds an M.S and a PhD from Indian Institute of Science, India and postdoctoral experiences from University of Miami, Miami University and University of Missouri.

Dhanalakshmi Sivanandhan is Associate Vice President of Biology at Jubilant Therapeutics Inc., a subsidiary of Jubilant Life Sciences Ltd.

Previously, Dhanalakshmi worked as Head of Oncology therapeutic area at Jubilant Biosys Ltd., where she executed close to 25 Oncology discovery projects delivering three pre-clinical candidates and out-licensed one of the in-house projects to a US based Biotech.

Prior to joining Jubilant in 2007, Dhanalakshmi has completed two post-doctoral trainings, at National Cancer Center, Tokyo, Japan and at University of Colorado Health Sciences Center, Denver, USA. She received her Ph.D in Life Sciences (Cancer research) from Jawaharlal Nehru University, New Delhi, India.